Abstract
Treatment of superficial bladder cancer using BCG as an immunotherapeutic agent has proved effective. Stringent safety procedures have been introduced at Yeovil District Hospital so that this treatment is available to patients with bladder cancer, while ensuring that other patients and staff are protected from the possibility of BCG cross-infection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have